Published in Gene Therapy Weekly, February 24th, 2000
"A dengue virus type 2 (den-2) DNA vaccine containing preM and E genes, and a recombinant maltose binding protein fusion protein containing the 'B' domain of den-2 envelope (MBPD2E), both elicit neutralizing antibody responses in vaccinated mice," reported M. Simmons and colleagues from the Naval Medical Research Center and Uniformed Services University of the Health Sciences, Maryland, USA.
"In an attempt to achieve superior antibody responses, we a) primed mice with...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.